On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008.
Since the announcement as of 15 August 2008, the following transactions have been made under the programme:
|
|
Number of shares |
Average purchase price |
Transaction value, DKK |
|
15 August 2008 |
50,000 |
310.5600 |
15,528,000 |
|
18 August 2008 |
50,000 |
310.1800 |
15,509,000 |
|
19 August 2008 |
60,000 |
299.9000 |
17,994,000 |
|
20 August 2008 |
50,000 |
298.3600 |
14,918,000 |
|
21 August 2008 |
50,000 |
295.1700 |
14,758,500 |
|
22 August 2008 |
50,000 |
292.7000 |
14,635,000 |
|
Accumulated under the programme |
310,000 |
|
93,342,500 |
Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 51,070 B-shares in the period from 14 August 2008 to 21 August 2008. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 21,522,960 treasury shares, corresponding to 3.4% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
|
Media: |
Investors: |
|
|
|
|
|
|
|
Mette Kruse Danielsen |
Mads Veggerby Lausten |
|
Tel: (+45) 4442 3883 |
Tel: (+45) 4443 7919 |
|
|
|
|
|
Hans Rommer |
|
|
Tel: (+45) 4442 4765 |
|
|
|
|
|
|
|
In North America: |
|
|
Sean Clements |
|
|
Tel: (+1) 609 514 8316 |
|
|
|
Company Announcement no 53 / 2008